Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CLL11 trial (obinutuzumab): what clinicians have said so far
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
- NCT01010061 ↗
- Completed
- Hoffmann-La Roche
- Deep size, estimated: 301+ verified statements
We haven't built an HCP commentary report on CLL11 (obinutuzumab in previously untreated chronic lymphocytic leukemia with comorbidities) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CLL11 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 15 posts on X | |
| 8 YouTube videos | |
| 5 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- obinutuzumab; rituximab; chlorambucil
- Arms
- obinutuzumab + chlorambucil (GClb) · Experimental
- rituximab + chlorambucil (RClb) · Active comparator
- Chlorambucil (Clb) · Active comparator
- Enrollment
- 787
- Primary outcomes
- Progression-free Survival (PFS)
- Percentage of Participants With Progression Free Survival Events
- Sponsor
- Hoffmann-La Roche with German CLL Study Group, Genentech, Inc.
- Start
- Dec 21, 2009
- Primary completion
- Jul 1, 2012
- Results posted
- Yes
- Registry record
- NCT01010061 · updated Sep 14, 2018
Publications
linked from the registry- Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Furstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood. 2024 Jun 20;143(25):2588-2598. doi: 10.1182/blood.2023022564. PubMed 38620092
- Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Dohner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2020 Nov 1;105(11):2598-2607. doi: 10.3324/haematol.2019.231027. PubMed 33131249
- Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, Jamois C. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol. 2019 Sep;85(9):1935-1945. doi: 10.1111/bcp.13974. Epub 2019 Jul 12. PubMed 31050355
- Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8. PubMed 24401022